The STARRT-AKI Study will compare immediate initiation of RRT with a delayed approach to initiation of RRT for patients with severe AKI in ICU to assess the impact upon all-cause mortality at 90 days. 2,866 participants will be recruited globally, from over 100 sites throughout Australia, New Zealand, China, Canada, Europe, the United States and South America. The study population will consist of adult patients admitted to intensive care units with severe AKI who meet the full eligibility criteria for RRT.
STARRT-AKI is coordinated in collaboration with project originators Sean Bagshaw (University of Alberta) and Ron Wald (St Michael’s Hospital, University of Toronto) and the Applied Health Research Centre at St Michael’s Hospital in Toronto, Canada. The George Institute is a Regional Coordinating Centre, managing sites in Australia, New Zealand and China.
The TTM2 trial is an international, multicentre, parallel group, non-commercial, randomised, superiority trial in which a target temperature of 33°C after cardiac arrest will be compared with normothermia and early treatment of fever (Ø37.8°C) Patients eligible for inclusion will be unconscious adult patients with out-of-hospital cardiac arrest of a presumed cardiac cause with stable return of spontaneous circulation. Randomisation will be performed by a healthcare professional in the emergency department, in the angiography suite or in the intensive care unit via web-based application using permuted blocks with varying sizes, stratified by site. Due to the nature of the intervention, health care staff will not be blinded to the intervention. However, outcome assessors, prognosticators, statisticians and conclusion drawers will be blinded to group allocation.
Severe Community Acquired Pneumonia (severe CAP) is a major cause of mortality. The REMAP-CAP Trial is a multi-centre randomised controlled platform trial utilising Bayesian adaptive methods for 2800 Australian and New Zealand ICU patients with severe CAP to be analysed in conjunction with patients enrolled in other locations.
TEAM is a program of research to evaluate the effect of early mobilisation to assess functional recovery and patient-centred outcomes of ICU survivors. This includes (1) reviews and systematic reviews, (2) a multi-centre observational study to define standard care funded by the Intensive Care Foundation and endorsed by the ANZICS Clinical Trials Group. This pilot RCT was the third component of the TEAM program and its objective was to determine if a phase III RCT of early mobilisation was feasible in ICUs in Australia and New Zealand. Results from the pilot RCT will be used for a grant application to the NHMRC for a phase III RCT.
EPIC III (a 24-hour point-prevalence study) was performed on September 13, 2017, World Sepsis Day. Data was collected on: demographics, infection management, degree of organ dysfunction and patient outcomes. EPIC III is supported by the World Federation of Societies of Intensive and Critical Care Medicine.
WEAN SAFE (WorldwidE AssessmeNt of Separation of pAtients From ventilatory assistancE) is a multi-centre, prospective, observational, 4-week inception cohort study being carried out by the Acute Respiratory Failure section of ESICM. Weaning represents a challenge for intensivists and patients spend a considerable amount of time in being liberated from mechanical ventilation. While guidelines do exist on the classification of weaning, a recent study has shown that these may not be applicable to all patients. Moreover, different practices exist in regard to weaning procedures. WEAN SAFE will prospectively assess the burden of, management and spectrum of approaches to weaning from ventilation, in patients that require invasive mechanical ventilation for any reason, for a time period of at least 24 hours.
POSE (Peri-interventional Outcome Study in the Elderly) is an an investigator initiated European, multi-centre, observational cohort study. It will predict critical stages and outcomes in a large sample of all surgical and non-surgical interventional patients ≥80 years of age in Europe.